Raja Kunal, Ramrakhia Sonam, Dev Kapeel, Shahid Wajeeha, Sohail Hamza, Memon Muhammad Khizar, Memon Sidra
Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, PAK.
Medicine, Liaquat University of Medical and Health Sciences, Sukkur, PAK.
Cureus. 2020 Sep 30;12(9):e10729. doi: 10.7759/cureus.10729.
First-line treatment of Parkinson's disease (PD) includes a dopamine analog, levodopa, administered in combination with carbidopa to increase efficacy. Wearing-off (WO) phenomenon is a frequent complication which is defined as a reoccurrence of motor and non-motor symptoms during levodopa free interval, which has a negative impact on the quality of life of patients. Through this study, we aim to determine risk factors that lead to the manifestation of the WO phenomenon among patients presenting in our out-patient department of a tertiary care hospital in Pakistan.
A observational case-control study was conducted from April 2019 to December 2019 in a tertiary care hospital in Pakistan. A total of 101 patients who had PD were included in the study. They were randomized into two groups i.e. patients who had WO phenomenon (59 participants) and patients who did not experience WO (42 participants) phenomena. Patients were evaluated based on a self-administrated questionnaire. A p-value of less than 0.05 was considered significant.
WO was significantly higher in those patients who had earlier onset of Parkinson (59 ± 10 vs. 65 ±8; p<0.002) and had the disease for a longer duration (7.9±5.1 vs. 5.6±3.1, p<0.002). Other findings included, there was more risk of WO in patients on anti-parkinsonian treatment for longer duration (7.2±5.1 vs. 3.9±3.5, p<0.010) and on longer duration on levodopa treatment (6.9±4.9 vs. 3.1±2.8, p<0.0001).
Our study demonstrated several factors which are responsible for the WO phenomenon. This will aid neurologists to consider these risk factors while prescribing different treatment modalities for the disease to improve efficacy and mitigate WO effect among patients, specifically while advising levodopa.
帕金森病(PD)的一线治疗包括一种多巴胺类似物左旋多巴,并与卡比多巴联合使用以提高疗效。剂末现象(WO)是一种常见并发症,定义为在左旋多巴无药间期运动和非运动症状再次出现,这对患者的生活质量有负面影响。通过本研究,我们旨在确定在巴基斯坦一家三级护理医院门诊就诊的患者中导致剂末现象出现的危险因素。
2019年4月至2019年12月在巴基斯坦一家三级护理医院进行了一项观察性病例对照研究。共有101例帕金森病患者纳入研究。他们被随机分为两组,即有剂末现象的患者(59名参与者)和未经历剂末现象的患者(42名参与者)。患者通过自行填写问卷进行评估。p值小于0.05被认为具有统计学意义。
帕金森病发病较早的患者出现剂末现象的比例显著更高(59±10 vs. 65±8;p<0.002),且患病时间更长(7.9±5.1 vs. 5.6±3.1,p<0.002)。其他研究结果包括,接受抗帕金森病治疗时间较长的患者出现剂末现象的风险更高(7.2±5.1 vs. 3.9±3.5,p<0.010),以及接受左旋多巴治疗时间较长的患者出现剂末现象的风险更高(6.9±4.9 vs. 3.1±2.8,p<0.0001)。
我们的研究证明了几个导致剂末现象的因素。这将有助于神经科医生在为该疾病开不同治疗方案时考虑这些危险因素,以提高疗效并减轻患者的剂末现象影响,特别是在开具左旋多巴处方时。